<DOC>
	<DOC>NCT01317641</DOC>
	<brief_summary>The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.</brief_summary>
	<brief_title>Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Written informed consent Histologically confirmed adenocarcinoma of prostate Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral orchiectomy Progressive metastatic disease Adequate bone marrow, hepatic, and renal function Known metastases in the brain History of other malignancy within the previous 5 years Known gastrointestinal disease or procedure that affects the absorption Not able to swallow the study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>